GlassScriptPhysician profile
Alkeshkumar H Patel
NPI 1881616290
$1,439.16
in general payments reported to CMS, 2019-2025
26 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $171 · 2021: $272 · 2022: $323 · 2023: $304 · 2024: $85.65 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487 · Entertainment: $17.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.49 |
| Entertainment | $17.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $205.72 | 2019-2022 | |
| Nevro Corp. | $201.49 | 2021-2022 | |
| Lilly USA, LLC | $191.11 | 2019-2023 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $152.13 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $110.00 | 2020-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $98.24 | 2021-2023 | Confirm Rx, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.34 | 2019-2023 | |
| Glaxosmithkline, LLC. | $43.86 | 2023 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $38.29 | 2023 | Gvoke Hypopen |
| Intra-Sana Laboratories | $33.46 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ucb, INC. | $29.16 | 2025 | Briviact |
| Boston Scientific Corporation | $28.98 | 2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $27.64 | 2019-2021 | |
| Ethicon US, LLC | $26.44 | 2020 | |
| Avanir Pharmaceuticals, INC. | $24.04 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $21.44 | 2025 | Smartvest |
| Teleflex LLC | $19.45 | 2023 | Urolift |
| Optos, INC. | $17.33 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Janssen Pharmaceuticals, INC | $16.16 | 2020 | |
| Amgen INC. | $14.41 | 2023 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $14.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.03 | 2021 | |
| Impulse Dynamics (USA) INC. | $13.72 | 2022 | |
| Bardy Diagnostics, INC. | $13.57 | 2022 | |
| Abbvie INC. | $13.51 | 2021 | |
| Horizon Therapeutics Plc | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alkeshkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.